# ENDRA Life Sciences Inc.: Form 10-Q for the period ended Mar 31, 2026

- Company: [ENDRA Life Sciences Inc.](/companies/ndra.md) (CIK 1681682)
- Form: 10-Q
- Filed: 2026-05-15
- Accepted by EDGAR: May 15, 2026, 16:01 ET
- Period: 2026-03-31
- Accession: 0001213900-26-057680
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1681682/000121390026057680/ea0290744-10q_endra.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1681682/000121390026057680/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2026-01-01 to 2026-03-31 | $776.4k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2026-01-01 to 2026-03-31 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2026-01-01 to 2026-03-31 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-01-01 to 2026-03-31 | −$1.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-01-01 to 2026-03-31 | −$1.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-01-01 to 2026-03-31 | 1,199,586 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2026-01-01 to 2026-03-31 | −$1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2026-03-31 | $356.5k | us-gaap:Cash |
| Current assets | at 2026-03-31 | $536.7k | us-gaap:AssetsCurrent |
| Total assets | at 2026-03-31 | $3.4m | us-gaap:Assets |
| Current liabilities | at 2026-03-31 | $835.4k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-03-31 | $1.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2026-03-31 | $1.8m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1681682/000121390026057680/ea0290744-10q_endra.htm

Filed May 15, 2026.
Source: SEC EDGAR, the filing index for accession 0001213900-26-057680. Last ingested by Listed: Nov 6, 2026, 16:42 ET. No prices; not investment advice.